Beskrivelse
Dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl-4-piperidinemethanol (M100907) Attenuates Impulsivity after Both Drug-Induced Disruption (Dizocilpine) and Enhancement (Antidepressant Drugs) of Differential-Reinforcement-of-Low-Rate 72-s B", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol.327, no.3, December 2008 (2008-12), pages 891-897, XP002741249, ISSN: 0022-3565, GAISLER-SALOMON I ET AL: "Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered", PSYCHOPHARMACOLOGY, vol.196, no.2, February 2008 (2008-02), pages 255-267, XP002741250, ISSN: 0033-3158, M. L. CARLSSON ET AL: "The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice", JOURNAL OF NEURAL TRANSMISSION, vol.
106, no.2, 17 March 1999 (1999-03-17), pages 123-129, XP055040422, ISSN: 0300-9564, DOI: 10.1007/s007020050144, DE PAULIS T: "M-100907 (Aventis)", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol.2, no.1, 1 January 2001 (2001-01-01) , pages 123-132, XP009108036, ISSN: 1472-4472, WO-A1-2013/138322
Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/
Krav
IPC-klasse
Fullmektig i Norge:
Org.nummer: 918752900
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2012.07.12, US 201261741114 P
2012.07.12, US 201261741115 P
ARDAYFIO PAUL A ET AL: "The 5-Hydroxytryptamine(2A) Receptor Antagonist R-(+)-alpha-( 2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl-4-piperidinemethanol (M100907) Attenuates Impulsivity after Both Drug-Induced Disruption (Dizocilpine) and Enhancement (Antidepressant Drugs) of Differential-Reinforcement-of-Low-Rate 72-s B", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 327, no. 3, December 2008 (2008-12), pages 891-897, XP002741249, ISSN: 0022-3565 (B1)
WO-A2-2011/044089 (B1)
DE PAULIS T: "M-100907 (Aventis)", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 2, no. 1, 1 January 2001 (2001-01-01) , pages 123-132, XP009108036, ISSN: 1472-4472 (B1)
GAISLER-SALOMON I ET AL: "Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered", PSYCHOPHARMACOLOGY, vol. 196, no. 2, February 2008 (2008-02), pages 255-267, XP002741250, ISSN: 0033-3158 (B1)
HERESCO-LEVY U ET AL: "Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder", JOURNAL OF AFFECTIVE DISORDERS, ELSEVIER BIOCHEMICAL PRESS, AMSTERDAM, NL, vol. 93, no. 1-3, 1 July 2006 (2006-07-01) , pages 239-243, XP024997304, ISSN: 0165-0327, DOI: 10.1016/J.JAD.2006.03.004 [retrieved on 2006-07-01] (B1)
KR-A- 20070 017 136 (B1)
M. L. CARLSSON ET AL: "The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice", JOURNAL OF NEURAL TRANSMISSION, vol. 106, no. 2, 17 March 1999 (1999-03-17), pages 123-129, XP055040422, ISSN: 0300-9564, DOI: 10.1007/s007020050144 (B1)
ROGOZ Z ET AL: "Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 42, no. 8, 1 June 2002 (2002-06-01), pages 1024-1030, XP002288820, ISSN: 0028-3908, DOI: 10.1016/S0028-3908(02)00055-2 (B1)
SAHINER ET AL.: 'Memantine Improves Learning In Kindled Rats' JOUMAL OF NEUROLOGICAL SCIENCES vol. 28, no. 3, 08 September 2011, pages 322 - 329, XP019925492 (B1)
US-A1- 2009 176 715 (B1)
US-A1- 2011 207 776 (B1)
US-A1- 2011 306 586 (B1)
US-A1- 2012 041 026 (B1)
WO-A1-2012/104852 (B1)
WO-A1-2013/138322 (B1)
WO-A2-2005/000216 (B1)
WO-A2-2005/065308 (B1)
WO-A2-2006/058059 (B1)
CRANE G E: "Cycloserine as an antidepressant agent", AMERICAN JOURNAL OF PSYCHIATRY, AMERICAN PSYCHIATRIC PUBLISHING, INC, US, vol. 115, no. 11, 1 May 1959 (1959-05-01), pages 1025-1026, XP009158563, ISSN: 0002-953X (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
Patent opphørt | Ikke betalt årsavgift |
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Opphørt for ikke betalt årsavgift (3206)
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Påminnelse om ikke betalt årsavgift (3331) (PTEP2872139)
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210)
|
Utgående
EP Batch Varsel om betaling av første årsavgift (3319)
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende, AR238031603
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
31801639 expand_more expand_less | 2018.02.01 | 5500 | Håmsø Patentbyrå AS | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|